- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | GENFLEET-B (02595): PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 05.12.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST SITE INITIATED IN A REGISTRATIONAL STUDY OF GFH375 FOR METASTATIC PANCREATIC CANCER, AS FIRST-IN-WORLD ... | 1 | HKEx | ||
| 24.11.25 | GENFLEET-B (02595): PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| 22.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A PHASE IB/II STUDY OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, COMBINED WITH CETUXIMAB ... | 2 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.10.25 | Verastem stock falls after GenFleet's PDAC study shows lower efficacy data | 1 | Investing.com | ||
| 21.10.25 | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 20.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT EFFICACY DATA OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FOR PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS ... | 1 | HKEx | ||
| 19.10.25 | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | 580 | Business Wire | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| 16.10.25 | GENFLEET-B (02595): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 30.09.25 | GENFLEET-B (02595): 2025 INTERIM REPORT | 1 | HKEx | ||
| 29.09.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT ... | - | HKEx | ||
| 19.09.25 | GENFLEET-B (02595): DATE OF BOARD RESOLUTIONS AND DATE OF PUBLICATION OF INTERIM REPORT | 1 | HKEx | ||
| 19.09.25 | BRIEF: GenFleet shares double in heavily oversubscribed IPO | 1 | Bamboo Works | ||
| 18.09.25 | GENFLEET-B (02595): ANNOUNCEMENT OF ALLOTMENT RESULTS | 3 | HKEx | ||
| 18.09.25 | GENFLEET-B (02595): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.09.25 | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | -3,65 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | What Analysts Are Saying About CG Oncology Stock | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| BIONTECH | 100,90 | -0,10 % | Neue Zölle für AMD, OpenAI kauft bei der Konkurrenz von Nvidia, Rheinmetall weiter im Aufwind und BioNTech schürt neue Hoffnung | Die Börsen bleiben weiterhin geprägt von hohen Kursständen, wenngleich es hier und dort auch etwas Gegenwind zu verzeichnen gibt. Nicht jede vielbeachtete Aktie kann derzeit schon neue Rekorde schreiben.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.